Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GRI
GRI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GRI News
GRI Bio to Participate in Webull Webinar Series
Feb 05 2026
Newsfilter
GRI Biopress Reports $12 Million Net Loss for FY 2025
Feb 04 2026
seekingalpha
GRI Bio Reports Promising Phase 2a Results for GRI-0621
Jan 28 2026
stocktwits
GRI BIO INC - GRI-0621 Demonstrates Notable Genetic Enhancement in Lung Injury
Jan 28 2026
moomoo
GRI BIO INC REPORTS ENCOURAGING PHASE 2A RESULTS FOR GRI-0621 IN IPF
Jan 28 2026
moomoo
GRI Bio Secures New Patent Protection
Jan 26 2026
Newsfilter
GRI Bio Approves 1-for-28 Reverse Stock Split, Reducing Shares to 540K
Jan 21 2026
seekingalpha
Grainger Reports Net Income Surge to £202.6M Amidst Projected Earnings Decline
Jan 01 2026
Yahoo Finance
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
Dec 30 2025
Benzinga
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
Dec 30 2025
Benzinga
GRI Bio Closes $8 Million Public Offering to Advance Drug Development
Dec 12 2025
Globenewswire
GRI Bio Closes $8 Million Public Offering of Common Stock and Warrants
Dec 12 2025
Newsfilter
GRI Bio Prices Public Offering of 10.67M Shares at $0.75 Each, Raising $8M
Dec 11 2025
Globenewswire
GRI Bio Drug Demonstrates Potential for Lung Function Improvement in Patients with Thickened Lungs
Dec 11 2025
Benzinga
GRI Bio Reports Positive Phase 2a Results for GRI-0621 with No Serious Adverse Events Over 12 Weeks
Dec 10 2025
Globenewswire
GRI Bio Reports Positive Phase 2a Results for GRI-0621 with No Severe Adverse Events Over 12 Weeks
Dec 10 2025
Newsfilter
Show More News
